Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2399-3642
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells ; volume:5 ; number:1 ; day:11 ; month:11 ; year:2022 ; pages:1-13 ; date:12.2022
Communications biology ; 5, Heft 1 (11.11.2022), 1-13, 12.2022
- Creator
-
Schanin, Julia
Korver, Wouter
Brock, Emily C.
Leung, John
Benet, Zachary
Luu, Thuy
Chang, Katherine
Xu, Alan
Freitas, Naomi De
Luehrsen, Kenneth
Brehm, Michael A.
Wong, Alan
Youngblood, Bradford A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s42003-022-04207-w
- URN
-
urn:nbn:de:101:1-2023012522003303267606
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schanin, Julia
- Korver, Wouter
- Brock, Emily C.
- Leung, John
- Benet, Zachary
- Luu, Thuy
- Chang, Katherine
- Xu, Alan
- Freitas, Naomi De
- Luehrsen, Kenneth
- Brehm, Michael A.
- Wong, Alan
- Youngblood, Bradford A.
- SpringerLink (Online service)
Other Objects (12)
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
Sialic acid/Siglec axis regulates antibody-mediated neutrophil cytotoxicity towards cancer cells
ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
Section VIII: Agonistic
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
Regulation of the effective anti-tumor CD4+ T cell immunity by agonistic CD137 antibody
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
Die Rolle von Siglec-H und Siglec-15 in Infektionen und Autoimmunität
Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
Contribution of SIGLEC-11 and SIGLEC-16 receptors to neuro-inflammation and neurodegeneration
Fluorescence lifetime imaging ophthalmoscope and supplement of agonistic TrkB antibody in a glaucoma model
An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
Sialic acid/Siglec axis regulates antibody-mediated neutrophil cytotoxicity towards cancer cells
ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
Section VIII: Agonistic
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
Regulation of the effective anti-tumor CD4+ T cell immunity by agonistic CD137 antibody
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
Die Rolle von Siglec-H und Siglec-15 in Infektionen und Autoimmunität
Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
Contribution of SIGLEC-11 and SIGLEC-16 receptors to neuro-inflammation and neurodegeneration
Fluorescence lifetime imaging ophthalmoscope and supplement of agonistic TrkB antibody in a glaucoma model
An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
Sialic acid/Siglec axis regulates antibody-mediated neutrophil cytotoxicity towards cancer cells
ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
Section VIII: Agonistic
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
Regulation of the effective anti-tumor CD4+ T cell immunity by agonistic CD137 antibody
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
Die Rolle von Siglec-H und Siglec-15 in Infektionen und Autoimmunität
Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
Contribution of SIGLEC-11 and SIGLEC-16 receptors to neuro-inflammation and neurodegeneration
Fluorescence lifetime imaging ophthalmoscope and supplement of agonistic TrkB antibody in a glaucoma model